Topical ophthalmic cysteamine (Cystaran, Cystadrops) for corneal cystine crystal accumulation
Covers FDA‑approved ophthalmic cysteamine products (Cystaran, Cystadrops) for treatment of corneal cystine crystal accumulation in members with cystinosis when authorization criteria are met; applies to prior authorization and reauthorization requests.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Therapy
Authorization of 12 months may be granted when ALL of the following are met
Supported by package insert references.
Continuation of Therapy
Authorization of 12 months may be granted for continued treatment when any of the following are met
Reauthorization based on response or stability.
Not Medically Necessary
Any use of Cystaran or Cystadrops for indications other than treatment of corneal cystine crystal deposits in cystinosis is not covered under this policy.
All other indications beyond treatment of corneal cystine crystal deposits in cystinosis are considered experimental/investigational and not medically necessary.
Provider Actions and Documentation Requirements
Prior Authorization Required
Initial authorization may be granted for up to 12 months when diagnosis of cystinosis is confirmed by leukocyte cystine assay or genetic testing and the member has corneal cystine crystal accumulation.
- Authorization duration: up to 12 months
- Clinical requirement: confirmation of cystinosis by increased leukocyte cystine concentration or genetic testing
- Clinical requirement: documented corneal cystine crystal accumulation
Provider Action
Submit required documentation with the prior authorization request to avoid delays or denials.
- Include member identifiers and provider contact information on all submissions
- Ensure supporting clinical notes and testing results accompany the request
Documentation Required
Required documentation: assay demonstrating increased cystine concentration in leukocytes or genetic testing results supporting the diagnosis of cystinosis.
- Attach laboratory report of leukocyte cystine assay OR genetic testing report confirming pathogenic variants in CTNS gene
- Document presence of corneal cystine crystal deposits in ophthalmology exam notes
Off‑Label / Experimental Use
Use of Cystaran or Cystadrops for indications other than treatment of corneal cystine crystal deposits in cystinosis is considered experimental/investigational and not medically necessary.
- Off-label use not covered
Definitions
Background
Cystinosis is a rare metabolic disorder characterized by accumulation of cystine crystals in multiple tissues, including the cornea. Topical ophthalmic cysteamine formulations such as Cystadrops are indicated to reduce corneal cystine crystal deposits in adults and children with cystinosis and are used specifically for this ophthalmic manifestation of the disease.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.